Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $281

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $264 to $281.